A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

Study Summary

This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.

Conditions

Small-cell Lung Cancer Neuroendocrine Carcinomas Solid Tumor Show to Express DLL3

Interventions / Drugs

IDE849 durvalumab IDE161

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment208 participants

Primary Completion—

Lead SponsorIDEAYA Biosciences

Data Retrieved2026-04-11 04:16:36.812145+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.